Best Practices in the Treatment and
Management of Cystic Fibrosis: Managed Care Perspectives on the Role
of New Therapies
A continuing medical education
activity provided by NAMCP and AAMCN
This activity is an archive from the live session from the 2022 Fall
Managed Care Forum. If you participated in the live session, you are
not eligible for continuing education credits from this archive.
This activity is valid from March 1, 2023 to March 1, 2024
Instructions for CME/NCPD: Complete the pre-test, listen to the
audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name
and email address on the pre-test, evaluation and post-test. If you
close your internet browser without completing the post test, you
will have ONE more opportunity to complete. A score of 70% must be
achieved on the post test to receive continuing education credits.
If you do not pass the post test after two attempts, you will not be
eligible to try again. Once you complete the evaluation form and
score 70% or higher on your post test, you will automatically be
given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by
an educational grant from
Cystic fibrosis (CF), also known as mucoviscidosis, is a genetic
disorder that affects mostly the lungs but also the pancreas, liver,
kidneys and intestine. While newborn screening for cystic fibrosis
(CF) has led to greater recognition of disease, patients with CF
continue to experience severe disease complications and high rates
of health care resource utilization. Patients with CF require
lifelong, daily prophylactic regimens to prevent exacerbations and
improve disease symptoms to maintain lung function. However, CF
treatment is shifting from symptomatic management to targeting the
underlying CFTR mutations to manage disease progression and prevent
recurring complications associated with CF. Managed care
professionals have a significant role in informing patients with CF
and caregivers about these available and emerging treatment
interventions and ensuring access to therapies. Through member
surveys, interviews, outcome reports and past conference
evaluations, NAMCP has seen a great need for more education on the
newer treatments in CF. It is critical to provide medical directors,
practicing physicians, nurse case managers and other healthcare
professionals on the updated treatment paradigm and management
strategies in CF.
Upon completion of this
activity, participants will be able to:
Assess the clinical and economic
burden of cystic fibrosis, including factors that contribute to
poor prognosis and increased costs
Analyze current standards of care
and the disease-modifying potential of investigational CFTR
modulators in patients with CF
Identify patient and provider
barriers and challenges, including cost, that impact
identification and treatment of CF
Describe challenges and
opportunities in cystic fibrosis disease management, including
patient adherence, quality of life and total cost of care
Assess the managed care
considerations on CFTR modulator therapies, including
combination options, and explore where these agents fit in the
cystic fibrosis management paradigm
||Gary Owens, MD
Gary Owens Associates
|(Relevant Financial Relationships with Ineligible
Companies in the Last 24 Months):
Dr. Owens has no relevant financial relationship with an
ineligible company to disclose.
Williams, MD has no relevant financial relationships
with an ineligible company in the last 24 months to
Jeremy Williams has no relevant financial relationships
with an ineligible company in the last 24 months to
Jacqueline Cole, RN, MS, CMCN has no relevant financial
relationships with an ineligible company in the last 24
months to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity.
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
This activity is supported by an educational grant from
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
Click Here To Continue